AI
TNGX icon

Atria Investments’s Tango Therapeutics TNGX Stock Holding History

Atria Investments’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,822
Closed -$131K – 2151
2025
Q4 		$131K Buy
+14,822
New +$128K ﹤0.01% 1994

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Atria Investments's TNGX Position: Q1 2026 in Review

Atria Investments sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 14,822 shares — an estimated $131K sold.

Atria Investments first reported a position in TNGX in Q4 2025 and held it in 1 quarter. The position peaked at $131K in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Atria Investments reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Atria Investments sold 14,822 Tango Therapeutics shares in Q1 2026, an estimated $131K.
  • Atria Investments first reported a position in Tango Therapeutics in Q4 2025 and held it in 1 quarter.
  • Atria Investments's Tango Therapeutics position peaked at $131K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.